



Robert
R&D Director

Nina
CEO & MD

Bronwyn
Product Development
Director

Hamish
CFO & Co.Sec



Dimerix

Company Review


Dr Nina Webster
CEO & Managing Director

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Key achievements – FY21



✓ Phase 3 study in FSGS designed and preparing to initiate, with other pipeline products also progressing



✓ Two independent Phase 3 clinical studies underway in patients with COVID-19 respiratory complications




✓ DMX-200 manufacturing process optimised to improve commercial scalability and global logistics




✓ Favourable clinical efficacy and strong safety profile across multiple Phase 2 renal clinical studies demonstrated

✓ Orphan Drug Designation/accelerated approval pathway granted by US FDA, EU EMA and UK MHRA for FSGS



Development pipeline

5 product candidates in the pipeline, with 4 clinical opportunities



Renal Development Overview




Why FSGS: unmet need and market potential

FSGS: rare kidney disease characterized by inflammation and scarring of the kidney's filtration units, affecting children and adults

Renal failure in <5 years from diagnosis – dialysis or transplant

~20,000 FSGS patients in US with end-stage kidney disease - only ~1,000 receive kidney transplants each year

Unfortunately, FSGS comes back to attack the new kidney 30-50% of the time[^]





FSGS phase 3 study primary endpoint

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB



Single, seamless Phase 3 study design*



ARB: Angiotensin Receptor Blocker
eGFR: estimated Glomerular Filtration Rate

* Subject to review by biostatistician

** Accelerated Approval: Marketing approval for "serious conditions that fill an unmet medical need based on a surrogate or an intermediate clinical endpoint"



COVID-19 Respiratory Complications

Vaccines very important

but may not be sufficient to meet the virus challenges

DMX-200

- Company's approach is based on a clear scientific rationale, unique & potentially complementary to others being investigated globally
- If effective, could be equally effective against any strain as well as other pneumonias
- Could well provide an opportunity well beyond COVID-19

Vaccines

Significant proportion of population may still be susceptible to COVID-19 because they are:

- resistant to the vaccine
- cannot be vaccinated; or
- choose not to be vaccinated

Still likely that many patients will get infected and will end up with COVID respiratory complications and potentially long-COVID (symptoms that extend long beyond recovery from the virus)


Antivirals

May require characterisation of specific anti-viral target to be effective – and may be specific to only one type of virus or strain

Potential for side effects

Must be initiated immediately after infection – timing of which can be difficult if patient is asymptomatic

COVID-19 and pneumonia market potential



* REMAP-CAP background: <https://www.remapcap.org/background>


** WHO COVID dashboard: <https://covid19.who.int/>

*** <https://investors.gilead.com/news-releases/news-release-details/open-letter-daniel-oday-chairman-ceo-gilead-sciences>

Two phase 3 studies in COVID-19 patients

REMAP-CAP:

- >200 patients with COVID-19 pneumonia in ICU in Europe/UK
- WHO endorsed study
- Primary endpoint = 21 day mortality



CLARITY 2.0:

- >600 patients with COVID-19 respiratory complications in India
- Primary endpoint = 14 day WHO Clinical Health Score



Secondary endpoint: recovery and quality of life post hospitalisation (long-COVID assessment)



Dimerix

A biopharmaceutical
developing innovative m
in areas with unmet m



Drug
m

Additional longer
term propositions

Additional asset value propositions

Longer term opportunities


Chronic Obstructive Pulmonary Disease



Global COPD treatment market (2017)

~US\$14 billion

Diabetic Kidney Disease



Addressable market

~US\$1.1 billion


Key driver is the rise in diabetes global incidence

Diversifying
risk and
potential
sources of
revenue

Financial Outcomes & Value Driving Events



FY2021 financial outcomes



Cash Reserve we had at June 2021

\$5.3 million*

Amount we invested in our product portfolio in FY2021

\$9.3 million

The number of Phase 2 clinical studies completed in the financial year

2

The number of Phase 3 stage opportunities in the pipeline

3

Corporate overview



ASX Ticker Symbol

ASX:DXB



Share price

~A\$0.31



Total ordinary shares on issue

248,499,122



Market Capitalisation

~A\$77 million



Average volume

934,479



Cash Balance (30Jun21)

A\$5.3 million*




Top 20 Shareholders own

30.1%

**excludes 20 million Placement announced in August 2021, and \$2 million SPP*



Chart generated on 25/9/2021 at 10:35 am



Top shareholders**

Position	Holder Name	Holding	% IC
1	MR PETER MEURS	26,529,309	10.7%
2	BAVARIA BAY PTY LTD	7,316,992	2.9%
3	YODAMBAO PTY LTD	6,212,603	2.5%
4	THE TRUST COMPANY LIMITED (Merchant Group)	5,843,536	2.4%
5	SOLEQUEST PTY LTD AND NOMINEES	3,029,478	1.2%
6	PFLEGER FAMILY A/C AND NOMINEES	2,387,874	1.0%
7	JAMPASO PTY LTD AND NOMINEES	2,252,355	0.9%
8	MR RICHARD STANLEY DE RAVIN	2,200,000	0.9%
9	TOROHA PTY LTD	2,044,932	0.8%
10	MR TAYLOR NICHOLAS GREEN	2,000,000	0.8%
TOTAL (TOP 10)		59,817,079	24.1%

**excluding Tranche 2 Placement and SPP

2021 & 2022 news flow*

2021

2022

- ✓ DMX-200 demonstrated **encouraging clinical efficacy** and **strong safety profile** across multiple Phase 2 renal clinical studies
- ✓ Consistent advice received from **FDA, EMA and UK MHRA** on FSGS Phase 3 study design
- ✓ Orphan Drug Designation/**accelerated approval pathway** granted by US FDA, EU EMA and UK MHRA for FSGS
- ✓ Two independent Phase 3 clinical studies underway in patients with **COVID-19 respiratory complications**
- ✓ DMX-200 **manufacturing process optimised** to improve commercial scalability and global logistics
- ✓ DMX-700 in COPD progressed further towards **clinical development**
- ✓ Expansion of **IP portfolio**
- ✓ Strong **financial position**

- FSGS **ethics approval** and clinical **site initiations**
- FSGS Phase 3 study **recruitment** and first patient **first visit**
- REMAP-CAP Phase 3 COVID-19 study recruitment and **initial data**
- CLARITY 2.0 Phase 3 COVID-19 study recruitment and **initial data**
- DMX-700 for Chronic Obstructive Pulmonary Disease progression towards **clinical study**
- Diabetic kidney disease **clinical study** design and next steps
- Further expansion of **IP portfolio**
- FSGS **Phase 3 study Part 1 analysis** and progression to Part 2 (end CY22)

Questions?



“We are profoundly aware of the potential impact Dimerix may have in improving the lives of millions of people around the world with both respiratory and renal conditions”

*Dr Nina Webster
CEO & Managing Director*